The research team, led by Anthoinette A. Ekuban and Frank E. Baiden, enrolled 644 children aged 5 to 17 years who visited Ho Polyclinic between January and June 2025 with a range of disease conditions. Rather than relying on a single snapshot, the investigators used a prospective longitudinal design: after the initial clinic visit, trained research assistants followed each child for fourteen calendar days, corresponding to roughly ten school days, contacting caregivers by phone or in person to record how many school days were missed, whether the child returned to class, and whether any new symptoms emerged. Follow-up data were recorded for 98.1 percent of enrolled children, a remarkably complete capture rate for this kind of fieldwork, and the number of days missed was documented for 426 children.

The headline result was striking. Of the children followed, 66.3 percent missed school due to their illness episode. That figure is far higher than population-based estimates from other settings, such as the 4.9 percent absenteeism reported among school-going children in India or the 5.8 percent chronic absenteeism recorded in the United States, but the comparison comes with an important caveat. Those population figures draw on all school-age children regardless of whether they are unwell, whereas this study sampled only children sick enough to seek care at a clinic. Similar facility-based studies have reported comparable rates, including 72.5 percent absenteeism among clinic-attending school children in Nigeria and frequent class absence among 70 percent of students with malaria in Ibadan. The pattern suggests that once a child is ill enough to reach a health facility, lost schooling is almost the default outcome in this region.

The demographic findings carry their own surprises. In the adjusted multivariable model, both age and educational level were significantly associated with absenteeism, but in opposite directions. Children aged 10 to 13 years had 1.63 times the odds of missing school compared with those aged 5 to 9, and adolescents aged 14 to 17 had 2.51 times the odds. Yet children in junior high school had only 0.41 times the odds of absenteeism, and senior high school students just 0.28 times the odds, relative to primary school pupils. Because age and educational level are tightly correlated in this sample, with older children concentrated in the higher school levels, the authors argue that educational level is the more robust and consistent correlate. Primary school children emerged as the group at consistently highest risk of losing school days to illness.

The researchers offer several possible explanations for this protective pattern among older students. Junior and senior high school students may manage their own illnesses more effectively, feel stronger motivation to attend, or practice what epidemiologists call presenteeism, showing up in class despite mild symptoms. High-stakes examinations at these levels may also incentivise attendance even during illness, which would reduce measured absenteeism without necessarily reflecting better health. Caregiver behaviour may play a role as well: parents tend to be more protective of younger children and more likely to keep them home when they are unwell, while older children may be encouraged to push through minor ailments. The authors caution that the positive age association, once school level is accounted for, may partly reflect a subgroup of older children still enrolled in primary school, perhaps due to delayed enrolment, and they recommend testing an age-by-education interaction in future work. They also acknowledge that household income, parental education, and caregiver health literacy were not measured and could confound these relationships.

Perhaps the most technically interesting part of the study lies in its handling of symptom data. The seven recorded symptoms were severely inter-correlated; headache and fever, for instance, correlated at r = 0.97, and a cluster of chills, abdominal pain, cough, and vomiting showed variance inflation factors between 4.6 and 7.1. Rather than forcing all symptoms into a single mutually adjusted model, which would have produced unstable estimates, the team adjusted each symptom separately for age, sex, educational level, and principal diagnosis. The results upended expectations. Skin rashes showed the strongest association with absenteeism, with an adjusted odds ratio of 1.91, followed by chills at 1.87 and abdominal pain at 1.69. Fever, cough, vomiting, and headache were not significantly associated with missed school once the other factors were accounted for, a genuinely different conclusion from earlier analyses that did not address the underlying collinearity.

The authors had originally hypothesised that fever, cough, and vomiting would dominate, consistent with prior literature linking respiratory and febrile illness to absence. Their interpretation of the actual pattern is that skin conditions, which were the most common principal diagnosis in the sample at 37.3 percent, are visible to caregivers and teachers and therefore prompt more consistent school exclusion, while chills and abdominal pain often signal systemic illness that demands caregiver attention even when fever itself is not documented. Dermatological conditions were followed by respiratory conditions at 11.8 percent, diarrhoeal disease at 11.3 percent, and malaria at 9.5 percent among the principal diagnoses. Notably, no diagnostic category was independently significant in the adjusted socio-demographic and diagnostic model, suggesting that the symptom profile and the child’s school level matter more than the formal diagnosis label in predicting who stays home.

The study’s methodological strengths are considerable for a single-facility investigation. Clinical assessments and laboratory investigations, including haemoglobin testing, malaria rapid diagnostic tests, and sickling tests, allowed diagnoses to be verified rather than relying solely on caregiver recall. The sample of 644 consecutively recruited children yielded 421 events in the main model, an events-per-variable ratio of 28.1, comfortably above accepted thresholds, and model fit was satisfactory by both Hosmer-Lemeshow testing and an area under the receiver operating characteristic curve of 0.648. The prospective two-week follow-up captured additional school days missed beyond the initial visit, and the study addresses an age group, 5 to 17 years, that is chronically under-represented in Ghana’s routine child-health data, which have historically prioritised children under five in line with global child-survival agendas.

The limitations are equally clearly stated. Because the sample was restricted to children who sought care at one polyclinic, the findings likely overestimate absenteeism relative to the general child population and cannot be generalised municipality-wide. Symptoms were recorded as present or absent from caregiver recall at a single time point, without severity or duration, both of which likely influence attendance decisions. Time from symptom onset to care-seeking was not measured, so the high absenteeism may reflect a combination of illness severity, delayed care-seeking, and caregiver decision-making that the present data cannot disentangle. Several adjusted estimates, particularly for mode of transport, carry wide confidence intervals reflecting small subgroup sizes.

The practical implications are nonetheless concrete. The authors recommend that health workers at first-contact facilities routinely ask about school attendance during illness visits, especially when children present with chills, abdominal pain, or skin rashes, so that the educational impact of illness becomes part of clinical management. Schools, particularly primary schools where risk was highest, should implement health programmes and regular screening to detect and treat illness before absences accumulate. Health education targeted at caregivers of primary-school-aged children should address the timing of care-seeking and safe return to school. The authors also flag a double-edged concern: if older students attend school while symptomatic, they may spread infections to classmates and teachers, a possibility with direct implications for outbreak control that deserves dedicated study. As the authors conclude, common acute illnesses remain a major contributor to lost schooling among care-seeking children, and strengthening collaboration between the health and education sectors could convert these epidemiological insights into classrooms that stay full.

Subject of Research: Illness-related school absenteeism and its socio-demographic and clinical correlates among school-aged children in Ho Municipality, Ghana

Article Title: Illness-related school absenteeism among children attending a primary healthcare facility: Socio-demographic and clinical correlates in Ho municipality, Ghana

Article References: Ekuban, A. A., & Baiden, F. E. (2026). Illness-related school absenteeism among children attending a primary healthcare facility: Socio-demographic and clinical correlates in Ho municipality, Ghana. Public Health in Practice, 12, Article 100863. https://doi.org/10.1016/j.puhip.2026.100863

Image Credits: AI Generated

DOI: 10.1016/j.puhip.2026.100863

Keywords: school absenteeism, child health, Ghana, primary healthcare, skin rashes, chills, abdominal pain, malaria, dermatological conditions, public health, sub-Saharan Africa, school health programmes

The findings arrive at a moment when irritable bowel syndrome has become one of the most common and frustrating diagnoses in gastroenterology. Classified among disorders of gut-brain interaction, IBS produces abdominal pain, bloating, and disturbed bowel habits in the absence of visible structural damage, and it resists most pharmacological treatments. That therapeutic vacuum has made acupuncture an increasingly popular option, and clinical trials have repeatedly reported that patients improve after a course of needling. But those trials also routinely show that patients receiving sham acupuncture improve nearly as much, raising a question that has shadowed complementary medicine research for decades: how much of the benefit is the needle, and how much is the mind?

To answer it, the researchers searched eight databases — PubMed, Embase, the Cochrane Library, Web of Science Core Collection, and four major Chinese databases including CNKI, Wanfang, VIP, and CBM — from their inception through July 4, 2026. They included only randomized controlled trials in which sham acupuncture served as a comparator in IBS patients, and they registered the protocol prospectively with PROSPERO under the identifier CRD420251035956. The primary outcome was the response rate, the proportion of patients who reported meaningful improvement, while secondary outcomes tracked changes in the IBS Symptom Severity Scale, the IBS Quality of Life scale, and abdominal pain intensity scores. Effect sizes were expressed as risk differences and pooled pre-to-post changes with 95 percent confidence intervals.

The headline numbers are striking. In patients who received sham acupuncture, the combined response rate was 0.38, meaning roughly 38 of every 100 patients treated with a placebo procedure reported feeling meaningfully better. On the IBS Symptom Severity Scale, scores fell by a pooled 60.08 points, with a confidence interval running from 70.62 down to 49.54 points of improvement. Quality of life scores rose by 8.23 points on average, and abdominal pain intensity dropped by 1.39 points on standard rating scales. None of these changes came from needles that penetrated classical acupoints in the way traditional theory prescribes; they emerged entirely from procedures intended to mimic acupuncture without its specific effects.

What does a 60-point drop on the symptom severity scale actually mean in clinical terms? The IBS-SSS is a 500-point instrument that captures pain intensity, pain frequency, bloating, satisfaction with bowel habits, and overall interference with daily life, and clinicians generally regard shifts of 50 points or more as clinically meaningful. By that yardstick, the placebo response documented in this analysis is not a statistical curiosity but a genuine therapeutic effect — one large enough that patients experience it as relief. Similarly, the 1.39-point reduction in pain intensity, measured on visual analog or numerical rating scales, represents a noticeable easing of the cramping and discomfort that define the condition.

Perhaps the most consequential part of the study, however, is not the headline effect size but the heterogeneity hiding beneath it. When the researchers stratified trials by their methodological and diagnostic characteristics, clear patterns emerged. Studies that used the Rome IV diagnostic criteria — the current international standard for defining functional gastrointestinal disorders — tended to report lower placebo responses than those relying on older Rome III or earlier criteria. Trials judged to be at low risk of bias also yielded smaller placebo effects, as did studies that defined treatment response according to the stringent criteria recommended by the U.S. Food and Drug Administration for IBS clinical trials. In other words, the more rigorous and modern the trial, the smaller the apparent power of the sham needle.

That pattern carries a lesson that extends well beyond acupuncture. Placebo responses are not fixed properties of a treatment; they are shaped by how trials are designed, how patients are selected, how outcomes are defined, and how much room subjective judgment has to wander. Older diagnostic criteria that swept in more heterogeneous patient populations, and looser definitions of what counts as a response, both inflate the apparent benefit of an inert procedure. The FDA’s patient-reported outcome requirements, which demand sustained improvement in abdominal pain and stool pattern rather than a fleeting global impression, are specifically engineered to filter out noise — and the analysis suggests they do exactly that, compressing the placebo response toward more conservative estimates.

The mechanisms behind a placebo response of this magnitude are likely multiple and overlapping. Ritualized, hands-on treatment delivers a dense bundle of contextual cues: a practitioner’s attention, the sensory experience of needling, the expectation of relief, and repeated clinical contact over weeks. IBS is, by definition, a disorder of gut-brain interaction, in which visceral sensitivity, stress physiology, and central pain processing are tightly entangled — making it precisely the kind of condition in which expectation and conditioning can plausibly modulate symptoms through real neurophysiological pathways. The gut’s enteric nervous system, its bidirectional communication with the brain via the vagus nerve and hypothalamic-pituitary-adrenal axis, and the endogenous opioid and cannabinoid systems all provide biological conduits through which psychological context can translate into altered gut sensation and motility.

For acupuncture researchers, the implications cut in two directions. On one hand, the substantial placebo response documented here means that any future trial of real acupuncture in IBS must be powered and designed to detect benefits that exceed this baseline — a demanding threshold, given that the sham arm already delivers clinically meaningful improvement to more than a third of patients. On the other hand, the finding does not automatically invalidate acupuncture as a therapy; it reframes the question. If part of acupuncture’s effect in IBS is a potent, ritual-mediated placebo response, some researchers argue that harnessing that response deliberately and ethically could itself be a legitimate clinical strategy, particularly for a condition with few effective drugs. The authors of the analysis note that several factors — diagnostic criteria, risk of bias, and response definitions — can notably influence the size of the placebo component, and that understanding these moderators is essential for interpreting both past and future trials.

For patients and clinicians, the study is a reminder that improvement after treatment is real even when the mechanism is expectation rather than needle stimulation — and that honest science can quantify that effect without dismissing the suffering it relieves. The 977 patients in these twelve trials who felt better after sham acupuncture were not imagining their symptoms fading; their brains and guts were genuinely recalibrating in response to context, ritual, and care. Disentangling how much of acupuncture’s benefit in IBS comes from specific needling effects and how much from this powerful contextual machinery will require trials that meet the highest methodological standards — Rome IV criteria, low risk of bias, and FDA-grade outcome definitions — and the new analysis provides the benchmark against which those trials can now be judged. In the meantime, it stands as one of the clearest quantitative demonstrations that in the contested territory of mind-body medicine, the placebo needle is anything but inert.

Subject of Research: Placebo response to sham acupuncture in patients with irritable bowel syndrome

Article Title: Placebo response of sham acupuncture in patients with irritable bowel syndrome: a systematic review and meta-analysis

Article References: Xiang, P., Wang, X., Li, B., Li, H., Zheng, W., Fan, X., Jiao, J., Wang, Y., Li, J., & She, Y. (2026). Placebo response of sham acupuncture in patients with irritable bowel syndrome: a systematic review and meta-analysis. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05513-0

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05513-0

Keywords: irritable bowel syndrome, sham acupuncture, placebo response, meta-analysis, systematic review, randomized controlled trials, IBS-SSS, gut-brain interaction, Rome IV criteria, abdominal pain, complementary medicine, clinical trial methodology

The retrospective analysis examined the medical files of 84 patients aged 21 years or younger who were diagnosed with colorectal cancer between 2012 and 2023 across 34 institutions participating in the Pediatric Surgical Oncology Research Collaborative. Crucially, the investigators excluded patients with known colorectal cancer predisposition syndromes, including hereditary genetic syndromes and inflammatory bowel disease, before their cancer diagnosis. That exclusion is what makes the findings so striking: these were largely sporadic cases, cancers that arose in young people with no identifiable inherited risk, in a population that current screening guidelines essentially do not cover.

The demographic and tumor characteristics paint a sobering picture. The median age at diagnosis was just 16.5 years, with an interquartile range of 14.0 to 19.0, and 56 percent of the patients were male. Of the 84 cancers identified, 65, or 77.4 percent, were colon adenocarcinomas, while 19, or 22.6 percent, were rectal adenocarcinomas. Among the colon cancers, the most common locations were the sigmoid colon and the ascending colon, each accounting for 27.7 percent of cases, and the cohort included five appendiceal adenocarcinomas, an unusually rare tumor type in any age group.

Perhaps the most consequential finding concerns family history. Only 20.2 percent of the patients, 17 individuals, reported having a first- or second-degree relative with colorectal cancer. That means the overwhelming majority of these young patients had no family signal that might have prompted earlier vigilance. In older populations, family history is one of the key triggers for earlier and more frequent screening, and its absence in most adolescent cases removes one of the few practical warning flags clinicians currently rely on.

The symptom profile at presentation was dominated by complaints that are easily attributed to far more benign causes in teenagers. Back or abdominal pain was the most common symptom, reported by 73.8 percent of patients, followed by changes in bowel habits at 45.2 percent, weight loss at 42.9 percent, and rectal bleeding at 38.1 percent. Each of these can be, and frequently is, explained away in young patients as constipation, dietary issues, stress, sports-related strain, or hemorrhoids. The study quantified the cost of that attribution error: the median duration of symptoms before diagnosis was 12 weeks, and the median time to colonoscopy was 13 weeks, delays measured in months of tumor growth in a disease that often behaves aggressively.

By the time diagnosis was finally made, the disease had frequently already advanced. The majority of patients presented with Stage III disease, 51.0 percent, or Stage IV metastatic disease, 29.0 percent, meaning roughly four in five young patients arrived with locally advanced or metastatic cancer. Study author Erica Arnold, MD, a pediatric surgery research fellow, emphasized the distinct nature of the disease in this population. “Colorectal cancer is, unfortunately, becoming more common in adolescents and young adults and represents a different disease than colorectal cancer diagnosed in older adults,” she said. “When diagnosed, it is often aggressive, presenting with late-stage disease and associated with high rates of disease relapse and mortality.”

The pathological features of the tumors support that characterization. On histologic examination, 33.3 percent of the tumors had signet ring features, 39.3 percent had mucin production, and 41.6 percent were poorly differentiated, all features associated with more aggressive biological behavior and worse prognosis. Treatment data reflected the difficulty of managing such disease: 62 patients, or 73.8 percent, underwent upfront surgical resection, while 4 patients, 4.8 percent, underwent attempted resection that could only achieve ostomy creation because the disease was unresectable. Fifteen patients, 17.9 percent, received neoadjuvant chemotherapy before surgery, and 3 patients, 3.6 percent, received definitive chemoradiation.

Outcomes were grim. Thirty-one patients, 36.9 percent, experienced relapse of their disease at a median of 11 months after treatment, and 96.8 percent of those who relapsed had been diagnosed with stage III or IV disease. Statistical analysis identified clear predictors of relapse: patients whose cancer returned were far more likely to have positive lymph nodes at diagnosis, 90.3 percent versus 50.9 percent, poorly differentiated histology, 64.5 percent versus 28.3 percent, and signet ring features, 61.3 percent versus 17.0 percent. All of the patients who relapsed had received adjuvant chemotherapy, underscoring that current treatment intensification was not enough to prevent recurrence in a substantial fraction of cases. By the end of the study period, 38 patients, 45.2 percent, had died as a result of their colorectal cancer.

The genetic testing results add another layer of scientific interest. Forty-six patients, 54.8 percent, underwent germline testing, and among those tested, 8, or 17.4 percent, carried a mismatch repair mutation, 4, or 8.6 percent, had a TP53 mutation, and 2, or 4.3 percent, had an APC mutation. These findings suggest that even among patients without a known predisposition syndrome at diagnosis, a subset harbor heritable mutations that may only be uncovered after cancer develops, reinforcing the argument for broader genetic evaluation in young-onset colorectal cancer and for cascade testing of relatives when mutations are found.

The study’s authors argue that the findings demand a change in clinical mindset rather than an immediate change in screening policy. Given the increasing incidence of adolescent colorectal cancer, practitioners should include the disease in their differential diagnosis when adolescents present with symptoms such as abdominal pain and rectal bleeding without an alternative explanation, taking unexplained weight loss and rectal bleeding in younger patients seriously. As early-onset adult cancers increasingly appear in younger and younger patients, the researchers note that the logistical coordination between adult and pediatric care teams, and carefully tailored treatment regimens, are paramount. For now, the message to clinicians and families alike is one of heightened vigilance: in a teenager with persistent, unexplained abdominal or back pain, altered bowel habits, weight loss, or rectal bleeding, colorectal cancer may be rare, but the data show it is no longer rare enough to ignore.

Subject of Research: Epidemiology and clinical presentation of sporadic colorectal carcinoma in pediatric and adolescent patients

Article Title: Colorectal cancer on the rise in adolescent patients

Article References: Colorectal cancer on the rise in adolescent patients. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: colorectal cancer, adolescent health, pediatric oncology, early-onset cancer, cancer screening, diagnostic delay, signet ring carcinoma, germline testing, American Academy of Pediatrics, cancer epidemiology, rectal bleeding, abdominal pain